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Abstract As part of the single technology appraisal (STA)
process, the National Institute for Health and Care Excellence
(NICE) invited Celgene Ltd to submit clinical and cost-effec-
tiveness evidence for paclitaxel as albumin-bound nanoparti-
cles (Nab-Pac) in combination with gemcitabine (Nab-
Pac ? Gem) for patients with untreated metastatic pancreatic
cancer. The STA was a review of NICE’s 2015 guidance
(TA360) in which Nab-Pac ? Gem was not recommended for
patients with untreated metastatic pancreatic cancer. The review
was prompted by a proposed Patient Access Scheme (PAS)
discount on the price of Nab-Pac and new evidence that might
lead to a change in the guidance. The Liverpool Reviews and
Implementation Group at the University of Liverpool was the
Evidence Review Group (ERG). This article summarises the
ERG’s review of the company’s evidence submission for Nab-
Pac ? Gem, and the Appraisal Committee (AC) decision. The
final scope issued by NICE listed three comparators: gemc-
itabine monotherapy (Gem), gemcitabine in combination with
capecitabine (Gem ? Cap), and a combination of oxaliplatin,
irinotecan, leucovorin and fluorouracil (FOLFIRINOX). Clin-
ical evidence for the comparison of Nab-Pac ? Gem versus
Gem was from the phase III CA046 randomized controlled trial.
Analysis of progression-free survival (PFS) and overall survival
(OS) showed statistically significant improvement for patients
treated with Nab-Pac ? Gem versus Gem. Clinical evidence
for the comparison of Nab-Pac ? Gem versus FOLFIRINOX
and versus Gem ? Cap was derived from a network meta-
analysis (NMA). Results of the NMA did not indicate a statis-
tically significant difference in OS or PFS for the comparison of
Nab-Pac ? Gem versus either Gem ? Cap or FOLFIRINOX.
The ERG’s main concerns with the clinical effectiveness evi-
dence were difficulties in identifying the patient population for
whom treatment with Nab-Pac ? Gem is most appropriate, and
violation of the proportional hazards (PH) assumption in the
CA046 trial. The ERG highlighted methodological issues in the
cost-effectiveness analysis pertaining to the modelling of sur-
vival outcomes, estimation of drug costs and double counting of
adverse-event disutilities. The AC accepted all the ERG’s
amendments to the company’s cost-effectiveness model;
however, these did not make important differences to the
incremental cost-effectiveness ratios (ICERs). The company’s
base-case ICER was £46,932 per quality-adjusted life-year
(QALY) gained for the comparison of Nab-Pac ? Gem versus
Gem. Treatment with Nab-Pac ? Gem was dominated both by
treatment with Gem ? Cap and with FOLFIRINOX in the
company’s base case. The AC concluded that the most plausible
ICER for treatment with Nab-Pac ? Gem versus Gem was in
the range of £41,000–£46,000 per QALY gained. The AC
concluded that Nab-Pac ? Gem was not cost effective com-
pared with Gem ? Cap or FOLFIRINOX, and accepted that
treatment with Nab-Pac ? Gem met the end-of-life criteria
versus Gem but did not consider Nab-Pac ? Gem to meet the
end-of-life criteria compared with Gem ? Cap or FOLFIR-
INOX. The AC also concluded that although patients who
would receive Nab-Pac ? Gem rather than FOLFIRINOX or
Gem ? Cap were difficult to distinguish, they were identifiable
in clinical practice. The AC recommended treatment with Nab-
Pac ? Gem for patients with untreated metastatic pancreatic
cancer for whom other combination chemotherapies were
unsuitable and who would otherwise receive Gem.
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Key Points for Decision Makers
There are no clear clinical parameters that can be
used to identify patients with untreated metastatic
pancreatic cancer for whom treatment with paclitaxel
as albumin-bound nanoparticles in combination with
gemcitabine (Nab-Pac ? Gem) is suitable.
Recognising the difficulty in identifying the
appropriate patient population and taking into
account that treatment with Nab-Pac ? Gem was
only shown to be cost effective versus treatment with
Gem, the Appraisal Committee recommended that
treatment with Nab-Pac ? Gem be made available
to patients for whom other combination
chemotherapies were unsuitable and who would
otherwise be treated with gemcitabine monotherapy
(Gem).
Findings from the CA046 trial, which is of good-
quality and mature, demonstrated that treatment with
Nab-Pac ? Gem is more efficacious than treatment
with Gem; however, lack of proportional hazards in
the trial means that hazard ratios for overall survival
and progression-free survival should be treated with
caution.
Only 10% of patients recruited to the CA046 trial
were aged C 75 years. In the National Health
Service (NHS), 47% of patients with pancreatic
cancer are aged C 75 years. This means that the
evidence from the trial may not be relevant to a
substantial number of NHS patients. The European
Medicines Agency advises caution when considering
using Nab-Pac ? Gem to treat patients
aged C 75 years due to a lack of evidence of clinical
efficacy and the adverse event profile.
No robust trial evidence is available to compare
treatment with Nab-Pac ? Gem with treatment with
a combination of oxaliplatin, irinotecan, leucovorin
and fluorouracil (FOLFIRINOX) or gemcitabine in
combination with capecitabine (Gem ? Cap). The
true effectiveness of treatment with Nab-Pac ? Gem
compared with Gem ? Cap or FOLFIRINOX
remains to be established.
Gem ? Cap and FOLFIRINOX are not licensed in
the UK for the treatment of metastatic pancreatic
cancer. As the components of both Gem ? Cap and
FOLFIRINOX are available as generics, there is no
single company with an interest in supporting the use
of either Gem ? Cap or FOLFIRINOX.
1 Introduction
The National Institute for Health and Care Excellence
(NICE) is an independent organization responsible for
providing national guidance to the National Health Service
(NHS) in England and Wales on a range of clinical and
public health issues, as well as appraisal of new health
technologies. The NICE Single Technology Appraisal
(STA) process is specifically designed for the appraisal of a
single health technology for a single indication, where most
of the relevant evidence lies with one company or sponsor
and typically covers new technologies shortly after UK
market authorisation is granted [1]. Within the STA pro-
cess, the company provides a written submission (including
a decision-analytic model) that summarizes the company’s
estimate of the clinical effectiveness and cost effectiveness
of the technology. An external independent organisation
(typically an academic group) known as the Evidence
Review Group (ERG), provides a critique of the company’s
submission (the ERG report).
Following a specification developed by NICE (the final
scope), the NICE Appraisal Committee (AC) considers the
company’s submission (CS), the ERG report, and testi-
monies from experts and stakeholders to determine whe-
ther the technology represents clinical and cost effective
use of NHS resources. All stakeholders and the public have
an opportunity to comment on the preliminary guidance
issued by NICE in the form of an Appraisal Consultation
Document (ACD), after which the AC meets again to
produce the final guidance (Final Appraisal Determination
[FAD]). The final guidance constitutes a legal obligation
for NHS providers in England and Wales to provide a
technology that is approved within its licensed indication
[1].
This article presents a summary of the ERG report by
the Liverpool Reviews and Implementation Group at the
University of Liverpool for the STA of paclitaxel as
albumin-bound nanoparticles with gemcitabine (Nab-
Pac ? Gem) for untreated metastatic pancreatic cancer.
Celgene Ltd was the sponsoring company for this STA.
This STA was a review of existing NICE guidance
TA360 [2], published in October 2015, in which NICE did
not recommend the use of Nab-Pac ? Gem as a treatment
for untreated metastatic pancreatic cancer. The review of
TA360 was prompted by a proposed Patient Access
Scheme (PAS) discount on the price of Nab-Pac and an
indication by the company that there was new evidence
available that might lead to a change in the existing rec-
ommendation. Full details of all documents relevant to this
appraisal (including the appraisal scope, ERG report,
company and consultee submissions, NICE guidance, and
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comments on each of these) can be found on the NICE
website [3].
2 The Decision Problem
Pancreatic cancer is the seventh most common cause of
cancer death worldwide [4]. More than 330,000 people
died of the disease in 2012, with mortality rates at their
highest in Europe and lowest in Africa (although these
statistics partly reflect the quality of data worldwide) [4].
In Europe, pancreatic cancer is the fifth most common
cause of cancer-related death and more than 104,000
people died from the disease in 2012 [4]. Pancreatic cancer
is also the fifth most common cause of cancer death in the
UK, with 8817 people dying from the disease in 2014 [5].
Pancreatic cancer survival rates have not improved in
the UK for 40 years. Less than 1% of patients in England
and Wales are expected to survive more than 10 years
beyond diagnosis, which ranks pancreatic cancer survival
rates the poorest of the 20 most common cancers [6]. This
poor prognosis is partly due to the proportion of patients
who are diagnosed with advanced disease. Approximately
69% of patients with pancreatic cancer in England and
Wales (whose stage is recorded) have stage IV disease at
diagnosis. Almost half (47%) of patients with pancreatic
cancer in England are diagnosed after presenting as an
emergency [7].
Early-stage pancreatic cancer is typically symptomless,
and the symptoms of late-stage disease are non-specific. If
the tumour compresses the bile duct, patients can present
with jaundice. Other symptoms include abdominal pain,
back pain and weight loss. Patients may also experience
diabetes or pancreatitis [8].
When considering treatment options for patients with
metastatic pancreatic cancer, factors including performance
status (PS), age, bilirubin level, previous treatment, cardiac
status and immune function are considered.
The standard of care in the NHS in England and Wales
is gemcitabine monotherapy (Gem). Gem was first rec-
ommended by NICE in 2001 for patients with a Karnofsky
PS (KPS) C 50 [9]. Two other (combination) cytotoxic
chemotherapy treatments are used in clinical practice in
England and Wales: gemcitabine ? capecitabine (Gem ?
Cap) and FOLFIRINOX, a combination of oxaliplatin,
irinotecan, leucovorin and fluorouracil (5-FU). Neither
Gem ? Cap nor FOLFIRINOX are licensed in Europe for
the treatment of pancreatic cancer, and neither treatment
has been appraised by NICE. In UK clinical practice,
where treatment with Gem ? Cap is available, it would be
considered as an option for patients with a good PS (e.g.
Eastern Cooperative Oncology Group [ECOG] PS 0/1)
[10]. Where treatment with FOLFIRINOX is available, it is
an option for patients with a good PS and very few minor
comorbidities [10]. Many of the treatment centres in the
UK offer a modified dose schedule of FOLFIRINOX to
reduce toxicity. A common modification is the omission of
the bolus dose of 5-FU. However, the clinical efficacy of
any modifications to the FOLFIRINOX regimen is not
established.
The treatment considered in this appraisal was Nab-
Pac ? Gem. Nab-Pac is a novel formulation that allows
paclitaxel to be administered without solvents. It is
licensed in Europe, in combination with Gem, for the first-
line treatment of adult patients with metastatic adenocar-
cinoma of the pancreas. Nab-Pac ? Gem is accepted for
use in NHS Scotland and NHS Wales, but was not rec-
ommended by NICE for use in NHS England after its
original appraisal in 2015. The appraisal discussed in the
present paper was prompted by the company’s provision of
new health-related quality of life (HRQoL) evidence and a
proposed PAS discount on the price of Nab-Pac.
3 Independent Evidence Review Group (ERG)
Report
The evidence provided by the company comprised an ini-
tial submission, a cost-effectiveness model (which is
commercial in confidence) and the company’s response to
the ERG’s clarification requests. The ERG report is a
summary and critical review of the evidence for the clinical
and cost effectiveness of the technology provided by the
company. The aims of the report were to:
• assess whether the evidence submitted by the company
conforms to the methodological guidelines issued by
NICE;
• assess whether the company’s interpretation and anal-
ysis of the evidence are appropriate;
• indicate the presence of other sources of evidence or
alternative interpretations of the evidence that could
help inform the development of NICE guidance.
In addition to providing this detailed critique, the ERG
modified several key assumptions and parameters within
the company’s economic model in order to explore the
robustness of the company’s results.
3.1 Clinical Evidence
The comparators specified in the final scope issued by
NICE were Gem, Gem ? Cap and FOLFIRINOX.
The company presented evidence for the clinical effec-
tiveness of Nab-Pac ? Gem from the CA046 trial (also
known as mPACT) [11]. The CA046 trial was an open-
label, multicentre, phase III, randomized controlled trial
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that was designed to investigate the efficacy and safety of
Nab-Pac ? Gem versus Gem in patients with untreated
metastatic adenocarcinoma of the pancreas. A total of 831
patients were randomized to receive either Nab-Pac ?
Gem (n = 431) or Gem (n = 430).
The final overall survival (OS) analysis from the CA046
trial was based on 692 deaths (80% of patients; data cut-
off: 17 September 2012) [11]. Median follow-up was
9.1 months in the Nab-Pac ? Gem arm and 7.4 months in
the Gem arm. An updated analysis of OS from the CA046
trial with an extended data cut-off was also reported (data
cut-off: 9 May 2013) [12]. At the time of the updated
analysis, 774 (90%) patients in the ITT population had died
and median follow-up was 13.9 months.
Treatment with Nab-Pac ? Gem was shown to improve
median OS significantly compared with treatment with
Gem (8.5 months vs. 6.7 months; hazard ratio [HR] 0.72,
95% confidence interval [CI] 0.62–0.83) [11]. The incre-
mental OS benefit of treatment with Nab-Pac ? Gem was
1.8 months in the final analysis and 2.1 months in the
updated analysis [11, 12]. The effect of Nab-Pac ? Gem
was consistent over time as survival rates were statistically
significantly higher in the Nab-Pac ? Gem arm than in the
Gem arm at both 1 year and 2 years (p\ 0.001 and
p = 0.02, respectively) [11]. All sensitivity analyses car-
ried out by the company showed a statistically significant
OS treatment effect in favour of patients treated with Nab-
Pac ? Gem. The estimate of treatment effect favoured
treatment with Nab-Pac ? Gem rather than Gem in all
subgroups, except patients with normal CA19-9 levels for
whom no conclusions could be drawn. Key results from the
final OS analysis are shown in Table 1 and from the
updated OS analysis in Table 2.
Treatment with Nab-Pac ? Gem was shown to improve
median progression-free survival (PFS) significantly com-
pared with treatment with Gem in the CA046 trial [11].
Table 1 shows an incremental PFS benefit of 1.8 months
for both PFS by independent review (HR 0.69, 95% CI
0.58–0.82) and PFS by investigator assessment (HR 0.61,
95% CI 0.52–0.71). At 1 year, PFS rates were greater in
the Nab-Pac ? Gem group compared with the Gem group
(16 vs. 9%, independent review; 12 vs. 4%, investigator
assessment).
The most common grade 3 or 4 adverse events (AEs)
associated with treatment with Nab-Pac ? Gem were
neutropenia, fatigue, metabolism and nutritional disorders,
peripheral neuropathy, thrombocytopenia and anaemia.
Although these AEs were also associated with treatment
with Gem and Nab-Pac monotherapies, they occurred more
frequently when patients were treated with Nab-
Pac ? Gem.
No HRQoL data were collected in the CA046 trial [11].
Instead, the company presented early HRQoL results from
the SIEGE trial [13], a phase II randomized trial designed
to compare two different treatment schedules of Nab-
Pac ? Gem; the trial does not provide a comparison of
Nab-Pac ? Gem with Gem. These data were collected
using the European Organisation for Research and Treat-
ment Cancer (EORTC) Quality-of-Life Questionnaire
(QLQ-C30). The company reported that Global Health
Scores were generally stable throughout treatment; how-
ever, towards the end of the six-treatment-cycle period,
data were difficult to interpret due to small patient numbers
(n = 22 in the appropriate arm at week 24).
To allow a comparison of the effectiveness of treatment
with Nab-Pac ? Gem versus Gem ? Cap and versus
FOLFIRINOX, the company performed a network meta-
analysis (NMA). Although a connected network could be
formed by including only trials that compared treatments
relevant to the decision problem, the company base-case
network of ten trials [11, 14–22] included only three trials
[11, 15, 16] that provided evidence for comparators listed
in the final scope issued by NICE (i.e. Gem, Gem ? Cap
and FOLFIRINOX). The company also performed a sen-
sitivity analysis using a reduced network that included only
the comparators listed in the final scope issued by NICE. In
terms of OS, the results from this sensitivity analysis
mirrored the results from the base-case analysis and did not
suggest a statistically significant treatment effect for
Gem ? Cap versus Nab-Pac ? Gem (HR 1.10, 95%
credible interval [CrI] 0.67–1.84) or for FOLFIRINOX
versus Nab-Pac ? Gem (HR 0.77, 95% CrI 0.58–1.01).
For PFS, the results of the sensitivity analysis also mirrored
the results from the base-case analysis which did not sug-
gest a statistically significant treatment effect for Gem ?
Cap versus Nab-Pac ? Gem (HR 1.17, 95% CrI
0.75–1.86); however, the results of the sensitivity analysis
did suggest a statistically significant treatment effect for
FOLFIRINOX versus Nab-Pac ? Gem (HR 0.68, 95% CrI
0.51–0.91), unlike in the company’s base-case analysis.
The results of the company’s base-case NMA and reduced
network sensitivity analysis are shown in Table 3. The
results from the company’s base-case NMA were used in
the company’s cost-effectiveness model.
Throughout the CS, the company maintained the posi-
tion that the only comparator to treatment with Nab-
Pac ? Gem was Gem. The company claimed that
Gem ? Cap was used only rarely within the NHS, there-
fore did not represent standard of care and was not a rel-
evant comparator. The company contended that patients
who are suitable for treatment with FOLFIRINOX are
easily identified in clinical practice and are clinically dis-
tinct from patients who would be treated with Gem but who
could be treated with Nab-Pac ? Gem. The company
contended that the use of Nab-Pac ? Gem in the NHS
would only displace the use of Gem and would not affect
A. Stainthorpe et al.
Table 1 CA046 trial primary and secondary efficacy endpoints (17 September 2012) Source: Company submission, Table 13
Efficacy variable Nab-Pac ? Gem [N = 431] Gem [N = 430] HR (95% CI) p value
OS
Events [n (%)] 333 (77) 359 (83) – –
Censored [%] 23 17 – –
Months [median (95% CI)] 8.5 (7.9–9.5) 6.7 (6.0–7.2) 0.72 (0.62–0.83) \ 0.001
12-month survival rate [% (95% CI)] 35 (30–39) 22 (18–27) – \ 0.001
PFS (independent review)
Events [n (%)] 277 (64) 265 (62) – –
Censored [%] 36 38 – –
Months [median (95% CI)] 5.5 (4.5–5.9) 3.7 (3.6–4.0) 0.69 (0.58–0.82) \ 0.001
12-month PFS rate [% (95% CI)] 16 (12–21) 9 (5–14) – –
PFS (investigator assessment)
Events [n (%)] 327 (76) 348 (81) – –
Censored [%] 24 19 – –
Months [median (95% CI)] 5.3 (4.4–5.5) 3.5 (3.3–3.7) 0.61 (0.52–0.71) \ 0.001
12-month PFS rate [% (95% CI)] 12 (8.3–16.0) 4 (1.9–6.5) – –
CI confidence interval, Gem gemcitabine, HR hazard ratio, Nab-Pac ? Gem paclitaxel as albumin-bound nanoparticles in combination with
gemcitabine, OS overall survival, PFS progression-free survival
Table 2 Updated survival estimates in the CA046 trial (9 May 2013) Source: Company submission, Table 14
Nab-Pac ? Gem [N = 431] Gem [N = 430] HR (95% CI) p value
Events [n (%)] 380 (88) 394 (92) – –
Censored [n (%)] 51 (12) 36 (8) – –
Months [median (95% CI)] 8.7 (7.9–9.7) 6.6 (6.0–7.2) 0.72 (0.62–0.83) \ 0.0001
Survival rate, months [% (95% CI)]
6 66 (62–71) 55 (50–60) – –
12 35 (31–40) 22 (18–26)
24 10 (6–13) 5 (2–7)
36 4 (2–7) 0
42 3 (1–6) 0
CI confidence interval, Gem gemcitabine, HR hazard ratio, Nab-Pac ? Gem paclitaxel as albumin-bound nanoparticles in combination with
gemcitabine
Table 3 Results of company
network meta-analysis Source:
Company submission,
Figure 15, Figure 17 and
Table 40
Outcome Comparator Median HR vs. Nab-Pac ? Gem (95% CrI)
Company base case Reduced network sensitivity analysis
OS Gem ? Cap 0.970 (0.640–1.47) 1.10 (0.67–1.84)
FOLFIRINOX 0.77 (0.580–1.01) 0.77 (0.58–1.01)
PFS Gem ? Cap 1.15 (1.00–1.70) 1.17 (0.75–1.86)
FOLFIRINOX 0.77 (0.58–1.02) 0.68 (0.51–0.91)
CrI credible interval, FOLFIRINOX combination of oxaliplatin, irinotecan, leucovorin and fluorouracil,
Gem ? Cap gemcitabine in combination with capecitabine, HR hazard ratio, Nab-Pac ? Gem paclitaxel as
albumin-bound nanoparticles in combination with gemcitabine, OS overall survival, PFS progression-free
survival
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the current NHS usage of either Gem ? Cap or
FOLFIRINOX.
3.2 Critique of the Clinical Evidence
and Interpretation
The ERG considered that the company’s argument that
Gem was the only relevant comparator was not compelling.
The ERG noted that the company’s own market research
data suggested that although many patients in the NHS
receive Gem monotherapy, a proportion of patients receive
Gem doublet therapy (such as Gem ? Cap). The ERG
therefore considered the argument that Gem ? Cap was
not a relevant comparator due to its limited use to be
invalid. The ERG also considered that the company had
failed to define the patients who would be suited to treat-
ment with Nab-Pac ? Gem but not FOLFIRINOX. Clini-
cal advice to the ERG was that it would be difficult to
clearly establish which patients in the NHS would be better
suited to treatment with Nab-Pac ? Gem rather than with
FOLFIRINOX. The ERG considered that the issue of
identifying which patients are suitable for treatment with
Nab-Pac ? Gem, but not with FOLFIRINOX, remained
unresolved from TA360, and the ERG was unconvinced by
the company’s argument that FOLFIRINOX was not a
relevant comparator to Nab-Pac ? Gem.
The ERG considered that the CA046 trial [11] was of
good quality and well conducted. The trial data were
mature and, with no patient crossover, the results allowed
for reasonable conclusions to be drawn regarding the
clinical effectiveness of Nab-Pac ? Gem versus Gem in
the trial population. Substantial numbers of patients were
recruited and patient baseline characteristics were balanced
across both trial arms. The statistical methods used to
analyse trial data were generally appropriate. Clinical
advice to the ERG was that patients recruited to the CA046
trial [11] were younger and fitter than the population of
patients with metastatic disease treated in the NHS. Most
notably, only 10% of patients recruited to the trial were
aged C 75 years, whereas Cancer Research UK (CRUK)
statistics suggest that almost half (47%) of all patients
diagnosed with pancreatic cancer are in this age band [23].
None of the participating treatment centres were based in
the UK. The ERG considered the absence of HRQoL data
from patients in the CA046 trial to be disappointing. The
ERG also considered the HRQoL data from the phase II,
dose-scheduling SIEGE trial to have the greatest relevance
to the appraisal as it is a UK-based randomized trial that
recruited patients with metastatic pancreatic cancer. How-
ever, it noted that only the ‘concomitant arm’ (i.e. treat-
ment with Gem immediately after treatment with Nab-Pac)
of the trial was relevant to this appraisal, which did not
provide comparative data, and that only early results were
available.
The ERG conducted assessments to determine the
validity of the company’s assumption that survival hazards
were proportional over time, and thus that the HRs pre-
sented in the CS were appropriate. The ERG’s analyses
showed that over time the OS and PFS hazards from the
two arms of the CA046 trial [11] were not proportional.
Consequently, all HR results derived from the CA046 trial
[11] should be interpreted with caution. Furthermore, the
ERG highlighted that all of the company’s NMA results
(base-case and sensitivity analyses) were affected by the
lack of proportional hazards (PH) in the CA046 trial [11]
and these results should also be interpreted with caution.
Additionally, the ERG considered the results from the
company’s reduced NMA to be more appropriate than the
company’s base-case NMA results.
3.3 Cost-Effectiveness Evidence
The company adapted the model submitted within the
original submission to NICE for appraisal TA360 [2] rather
than constructing a de novo economic model. The company
used a Markov structure and employed an area under the
curve approach to estimating the proportion of patients
who transition between health states over time from the
start of treatment until death. There were three primary
health states in the model: pre-progression, post-progres-
sion and death. The pre-progression state was divided into
two secondary health states (pre-progression: on first-line
treatment; and pre-progression: off first-line treatment) to
more accurately estimate drug costs in cases where treat-
ment was discontinued before progression. The company
also included a tunnel state at 4 weeks to death to account
for a period of intensive palliative care in the final stages of
life.
Kaplan–Meier (K–M) data from the CA046 trial [11]
were used as the basis for estimating patient survival for
the comparison of treatment with Nab-Pac ? Gem versus
Gem. Stratified gamma curves were used to model OS, PFS
and time on treatment (TOT). Resource use and costs were
estimated based on information from the CA046 trial [11],
published sources and advice from clinical experts. A
confidential Department of Health PAS discount was
applied to the cost of Nab-Pac. Full list prices, accessed via
the drugs and pharmaceutical electronic market informa-
tion tool [24], the MIMS database [25] and the British
National Formulary [26] in January 2017, were used to
calculate the cost of all other drugs. No vial sharing was
assumed. Overall drug costs in the first-line setting were
subject to the assumption that 50% of all first-time dose
reductions and all subsequent dose reductions could be
anticipated, meaning that there would be no drug wastage
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from these reductions. The company also assumed that
50% of all missed doses could be anticipated. Che-
motherapy administration costs, monitoring costs, AE
costs, and the cost of palliative and end-of-life care were
sourced from NHS reference costs 2015/2016 [27] and the
Personal Social Services Research Unit 2016 [28].
The company’s base-case analysis prediction was a
mean of 0.927 life-years (LYs) gained for patients
receiving Nab-Pac ? Gem, 0.725 LYs gained for patients
receiving Gem, 0.950 LYs gained for patients receiving
Gem ? Cap and 1.154 LYs gained for patients receiving
FOLFIRINOX.
As HRQoL data were not collected as part of the CA046
trial, the company instead adjusted published health state
utility values [29] for use in a UK population. These
adjusted values were used in the base-case analysis for pre-
progression (0.74) and progressive disease (0.67). The
company used EQ-5D-5L data from the ‘concomitant’ arm
of the SIEGE trial in separate scenario analyses.
The company submitted an updated model during the
clarification process to correct an error. The company’s
base-case incremental cost-effectiveness ratio (ICER) for
the comparison of treatment with Nab-Pac ? Gem versus
Gem from the updated model was £46,932 per quality-
adjusted life-year (QALY) gained. Treatment with Nab-
Pac ? Gem was dominated (more costly and generated
fewer QALYs) by treatment with both Gem ? Cap and
with FOLFIRINOX.
The company carried out a wide range of deterministic
sensitivity analyses for the comparison of treatment with
Nab-Pac ? Gem versus Gem. The results showed that the
most influential parameter was the treatment variable used
to parameterise OS.
The results of the company’s probabilistic sensitivity
analysis showed that Nab-Pac ? Gem had a 64% proba-
bility of being cost effective compared with Gem at a
willingness-to-pay threshold of £50,000 per QALY gained.
3.4 Critique of the Cost-Effectiveness Evidence
and Interpretation
The ERG considered the company’s model to be generally
well-structured and correctly implemented. The ERG
amended one structural feature in the calculation of total
LYs and QALYs. The three key issues that required
exploration by the ERG in the company’s model were HRs
used for treatment with Gem ? Cap and with FOLFIR-
INOX, costing of drugs, and modelling of TOT.
The company used HRs from its base-case NMA to
estimate time-to-event outcomes for treatment with
Gem ? Cap and with FOLFIRINOX, which relied on the
PH assumption holding for PFS and OS within the CA046
trial [11]. Since PH had been shown not to hold for PFS or
OS in the CA046 trial [11], using the results of the NMA in
the model produced unreliable estimates for OS, PFS and
TOT for treatment with Gem ? Cap and with FOLFIR-
INOX. The ERG also had concerns about the company’s
use of HRs with a stratified Gamma model as the Gamma
model is an accelerated failure time model rather than a PH
model. The ERG applied published HRs for treatment with
Gem ? Cap versus Gem [15] and with FOLFIRINOX
versus Gem [16] in the model to overcome the need for PH
to hold in the CA046 trial [11]; however, PH did not hold
for FOLFIRINOX versus Gem for either PFS or OS. The
ERG considered that results for the comparison of treat-
ment with Nab-Pac ? Gem versus Gem ? Cap and versus
FOLFIRINOX should be treated with caution.
The company estimated average treatment costs for the
intervention and comparators using only a limited range of
the vial sizes available to the NHS for each drug. By
incorporating all available vial sizes in the calculation of
drug costs, the ERG estimated lower average weekly costs
for each first-line treatment in the company model.
The ERG prefers the use of K–M data directly as far as
possible when time-to-event evidence comes from a single
trial, especially when the trial data are mature. The TOT
data from the CA046 trial (supplied by the company during
the clarification process) were complete and therefore
represented the best possible evidence of time spent on
treatment for the patients in that trial. However, the com-
pany used a fully parametric model to estimate TOT, which
introduced unnecessary uncertainties into the analysis and
resulted in an overestimation of TOT for both treatments.
The ERG re-estimated TOT for treatment with Nab-
Pac ? Gem and with Gem using K–M data directly from
the CA046 trial.
The company also used parametric models to estimate
PFS and OS for treatment with Nab-Pac ? Gem and with
Gem using mature data from the CA046 trial. The ERG
investigated remodelling PFS and OS for treatment with
Nab-Pac ? Gem and with Gem using K–M data as far as
possible, then appending a parametric tail to extrapolate
beyond the trial data. The ERG found that its remodelling
of PFS and OS for treatment with Nab-Pac ? Gem and
with Gem had only a small impact on the size of the ICERs
per QALY gained.
Other issues identified by the ERG included the double
counting of AE disutilities. The ERG provided two sce-
nario analyses that investigate the impact of using different
costs for some AEs and using a different source of utility
values. The impact of the ERG’s various amendments on
the company’s base-case ICER per QALY gained are
shown in Table 4.
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3.5 Conclusions of the ERG Report
The ERG considered that the evidence submitted by the
company largely reflected the decision problem defined in
the final scope issued by NICE, although direct clinical
effectiveness evidence was only available for the compar-
ison of the efficacy of Nab-Pac ? Gem versus Gem.
The ERG noted that since the PH assumption for OS and
PFS in the CA046 trial was violated, any HRs resulting
from that trial should be treated with caution. This was true
for the CA046 trial and the company’s NMA. The true
clinical effectiveness of Nab-Pac ? Gem compared with
Gem, Gem ? Cap or FOLFIRINOX remains to be
established.
The ERG considered that the company had failed to
clearly define the patient population for whom treatment
with Nab-Pac ? Gem is appropriate. The ERG remained
unconvinced by the company’s case for Gem as the only
comparator to Nab-Pac ? Gem.
The various changes implemented by the ERG for the
comparison of treatment with Nab-Pac ? Gem versus
Gem, treatment with Nab-Pac ? Gem versus Gem ? Cap
and treatment with Nab-Pac ? Gem versus FOLFIRINOX
yielded a mixture of effects. Incremental costs and incre-
mental benefits both increased and decreased depending on
the individual revision. However, none of the ERG’s
individual revisions or revised base-case scenarios yielded
ICERs under £30,000 per QALY gained for treatment with
Nab-Pac ? Gem against any of the comparators. Only the
comparison of Nab-Pac ? Gem versus Gem yielded
ICERs under £50,000 per QALY gained once all the
ERG’s revisions and scenarios were applied.
4 National Institute for Health and Care
Excellence Guidance
The AC reviewed the evidence available on the clinical and
cost effectiveness of Nab-Pac ? Gem alongside expert
testimony from clinical experts and patient representatives.
4.1 Clinical Need and Patient Perspective
The AC accepted that metastatic pancreatic cancer carries a
poor prognosis and that there are concerns with current
treatment options, i.e. that treatment with FOLFIRINOX is
more effective but can result in serious AEs, whereas
treatment with Gem is better tolerated but is less effective.
It heard from the patient expert that many patients would
be willing to accept some additional side effects from
treatment if it resulted in a longer life expectancy. The AC
recognised the value of additional treatment options in this
area.
4.2 Current Practice and Comparators
The AC heard from the clinical experts that FOLFIRINOX
was the preferred choice in clinical practice for treating
Table 4 Cost-effectiveness results: ERG revisions to company base case Source: ERG report, Table 47, Table 48 and Table 49
Description Nab-Pac ? Gem vs.
Gem
Nab-Pac ? Gem vs.
Gem ? Cap
Nab-Pac ? Gem vs.
FOLFIRINOX
Company original base case £46,657 Dominated Dominated
Company updated base case £46,932 Dominated Dominated
ERG corrected company base case £47,011 Dominated Dominated
R1) HRs for Gem ? Cap vs. Gem – £103,827 –
R2) HRs for FOLFIRINOX vs. Gem £47,012 Dominated £3327
R3) ERG drug-costing method £39,289 Dominated Dominated
R4) TOT from CA046 trial £49,922 Dominated Dominated
R5) Do not apply AE disutilities £46,994 Dominated Dominated
R6) ERG OS £46,681 Dominated Dominated
R7) ERG PFS £46,933 Dominated Dominated
ERG revised base case (R3, R4, R5, R6, R7) £41,250 – –
ERG revised base case (R1, R3, R4, R5, R6,
R7)
– £99,837 –
ERG revised base case (R2, R3, R4, R5, R6,
R7)
– – Dominated
AE adverse event, ERG Evidence Review Group, FOLFIRINOX combination of oxaliplatin, irinotecan, leucovorin and fluorouracil, Gem
gemcitabine, Gem ? Cap gemcitabine in combination with capecitabine, HRs hazard ratios, Nab-Pac ? Gem paclitaxel as albumin-bound
nanoparticles in combination with gemcitabine, Nab-Pac ? Gem paclitaxel as albumin-bound nanoparticles in combination with gemcitabine,
PFS progression-free survival, OS overall survival, TOT time on treatment
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patients with untreated metastatic pancreatic cancer. It
understood that FOLFIRINOX is associated with better
survival rates but that it can be associated with serious
AEs. It heard that patients who were not considered fit
enough for treatment with FOLFIRINOX would be offered
Gem monotherapy. The clinical experts indicated that there
exists a group of patients in clinical practice who are not fit
enough to tolerate FOFIRINOX but who would be fit
enough to tolerate Nab-Pac ? Gem. The AC heard that this
group of patients is not easy to define using specific criteria
as it depends on the interaction of a number of factors, such
as age, PS, comorbidities and patient willingness to accept
the considerable toxicity. Clinical experts explained that
Gem ? Cap is rarely used in clinical practice, but the AC
noted that there is evidence that Gem doublet therapy is
used in the NHS in England to treat pancreatic cancer.
The AC concluded that, although Gem monotherapy,
FOLFIRINOX and Gem ? Cap were all potentially rele-
vant comparators for patients with untreated metastatic
pancreatic cancer, Gem monotherapy was the most
appropriate comparator for a subpopulation of patients for
whom other combination therapies were not suitable.
4.3 Clinical Effectiveness
The AC noted that the CA046 trial [11] showed that
patients treated with Nab-Pac ? Gem had statistically
significantly longer OS and PFS, and higher response rates,
than those treated with Gem monotherapy. The AC noted
the ERG’s concern that older patients were under repre-
sented in the CA046 trial; however, the AC understood that
clinicians would be cautious about using Nab-Pac ? Gem
in an older population, therefore the evidence from the
CA046 trial was suitable for decision making. The AC
concluded that Nab-Pac ? Gem was more clinically
effective than Gem monotherapy.
The AC understood that there was uncertainty in the
effectiveness estimates for treatment with FOLFIRINOX
and with Gem ? Cap; however, it considered that the
NMAs presented were preferable to having no data at all on
the effectiveness of treatment with Nab-Pac ? Gem versus
FOLFIRINOX and versus Gem ? Cap. Noting the results
of the NMAs, the AC concluded that Nab-Pac ? Gem was
likely to be less clinically effective than treatment with
FOLFIRINOX, and similarly effective to Gem ? Cap.
The AC noted that Nab-Pac ? Gem was associated with
more AEs than Gem monotherapy. It heard that combina-
tion therapies were likely to result in increased AE rates
over monotherapies. The AC recognised that it was diffi-
cult to draw firm conclusions about the rates of AEs
between treatment with Nab-Pac ? Gem and Gem ? Cap
given the available data. The AC concluded that Nab-
Pac ? Gem may be associated with more AEs than Gem or
Gem ? Cap. The AC recalled that it concluded in TA360
[2] that a difference in AE profiles between treatment with
Nab-Pac ? Gem and FOLRINOX could not be reliably
determined from the available data.
4.4 Cost Effectiveness
The AC agreed that the company’s model was structured
appropriately and that the assumptions were generally
reasonable. The AC accepted the ERG’s amendments to
the company base case but noted that they did not make a
substantial difference to the cost-effectiveness estimates.
The AC noted that neither the company base case nor
any of the ERG scenarios took the estimated ICER for
treatment with Nab-Pac ? Gem versus Gem above
£50,000 per QALY gained. The AC concluded that the
most plausible ICER for treatment with Nab-Pac ? Gem
versus Gem was between £41,000 and £46,000 per QALY
gained. The AC noted that both the company base case and
ERG revised base case showed that treatment with Nab-
Pac ? Gem was dominated by treatment with FOLFIR-
INOX. It also noted that the company base case showed
that treatment with Nab-Pac ? Gem was dominated by
treatment with Gem ? Cap, whereas the ERG revised base
case yielded an ICER of £99,837 per QALY gained for the
same comparison. The AC was confident that, despite the
uncertainty in the analyses, treatment with Nab-Pac ?
Gem would not be considered a cost-effective treatment
versus Gem ? Cap or versus FOLFIRINOX.
4.5 End-of-Life Criteria
The AC noted that life expectancy for patients with
untreated metastatic pancreatic cancer was up to 6 months,
therefore the short life expectancy criterion was met. It
understood that the expected mean survival gain for treat-
ment with Nab-Pac ? Gem versus Gem was\ 3 months
(2.4 months), but recognised that this survival gain should
be considered in the context of the average survival of
patients with the condition. It therefore considered that the
life-extending criterion was met in the comparison of Nab-
Pac ? Gem versus Gem. However, the AC concluded that
there was no survival benefit shown in the comparison of
Nab-Pac ? Gem versus Gem ? Cap or versus FOLFIR-
INOX, therefore the life-extending criterion was not met
for these comparators. The AC therefore concluded that
treatment with Nab-Pac ? Gem met the end-of-life criteria
when compared with treatment with Gem, but not when
compared with treatment with Gem ? Cap or
FOLFIRINOX.
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4.6 Final Guidance
The AC recommended Nab-Pac ? Gem for patients with
untreated metastatic pancreatic cancer for whom other
combination therapies were unsuitable and who would
otherwise receive Gem monotherapy. The final guidance
was published by NICE in September 2017.
5 Conclusions
The key issue in this appraisal was not methodological but
rather about how to identify the appropriate population for
treatment with Nab-Pac ? Gem. Although the ERG con-
sidered that some of the company’s cost-effectiveness
methods and assumptions had limitations, none of the
ERG’s model amendments made important differences to
the estimated ICERs per QALY gained for the comparison
of Nab-Pac ? Gem versus Gem, Gem ? Cap or FOL-
FIRINOX. Since treatment with Nab-Pac ? Gem was only
shown to be cost-effective versus treatment with Gem, it
remained to identify a population for whom only Gem
would be a suitable treatment in current clinical practice.
Neither the company nor the clinical experts present at the
AC meeting could provide evidence or advice to help
definitively categorise the population who would have been
fit enough for treatment with Nab-Pac ? Gem, and for
whom treatment with FOLFIRINOX or Gem ? Cap would
not have been suitable and who would otherwise have
received treatment with Gem. Ultimately, the AC left the
decision about the appropriate population up to individual
clinicians on a case-by-case basis.
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